药物基因组学影响肾移植术后他克莫司疗效的研究进展
| 作者: |
1李欢,
1周玉生,
1李荣
1 南华大学药物药理研究所，湖南 衡阳 421001 |
| 通讯: |
李欢
Email: 642610447@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2017.04.037 |
摘要
他克莫司(tacrolimus，FK506)是从链霉菌属中分离出来的钙调磷酸酶抑制剂，是用于预防器官移植排斥反应的一线免疫抑制剂。他克莫司作为免疫抑制剂，具有良好的治疗效果。然而，其治疗窗狭窄和药动学个体差异巨大，容易导致免疫抑制不足或过度抑制而诱导肾毒性、糖尿病等不良反应，目前是困扰临床实践的关键问题。
关键词：
他克莫司
药物基因组学
CYP3A
MDR1
SUMO4
Research progress of pharmacogenomics on the curative effect of tacrolimus after renal transplantation
CorrespondingAuthor: LI Huan Email: 642610447@qq.com
DOI: 10.3978/j.issn.2095-6959.2017.04.037
Abstract
Tacrolimus (Tacrolimus, FK506) is a calcineurin inhibitor isolated from Streptomyces, and it is a first-line immunosuppressive agent for the prevention of organ transplant rejection. Tacrolimus is an immunosuppressive agent with good therapeutic effect. However, the narrow therapeutic window and pharmacokinetics of individual differences easily lead to insufficient immunosuppression or excessive immunosuppression and adverse reactions induced by renal toxicity and diabetes, which remains a critical problem in clinical practice.